AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer
March 2, 2026
Evofem Biosciences Strengthens Board of Directors
August 3, 2022
Related Post
-
-
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress
March 2, 2026
-
SAB BIO to Participate in Upcoming Investor Conferences
March 2, 2026
-
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study
March 2, 2026